Clinical Trials Browser

Thymus Neoplasms, Neuroendocrine Tumors

NCT06441331 2025-12-17

KinLET

CNSEndocrineGastrointestinalLymphoidNETSarcoma

Gastro-enteropancreatic neuroendocrine tumor, Lymphoma, Rhabdomyosarcoma, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral, Neuroendocrine Tumors

NCT04919226 2025-09-10

COMPOSE

Phase 3 Active not recruiting

259 enrolled

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

NCT05387603 2025-09-10

START-NET

Phase 3 Recruiting

300 enrolled

EndocrineNET

Neuroendocrine Tumors

NCT03049189 2025-05-30

COMPETE

Phase 3 Active not recruiting

309 enrolled

EndocrineNET

Neuroendocrine Tumors

NCT06045260 2024-08-13

LUFOR

Phase 2 Recruiting

100 enrolled

CNSEndocrineNET

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT04276597 2023-03-10

PUTNET

Phase 2 Withdrawn

CNSDermatologicEndocrineNET

Neoplasms, Unknown Primary, Paraganglioma, Pheochromocytoma, Carcinoma, Merkel Cell, Neuroendocrine Tumors

NCT04915144 2023-02-21

177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs

Phase 2 Withdrawn

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Vipoma, Insulinoma, Gastrinoma, Neuroendocrine Tumors

NCT04790708 2021-03-10

FENET-2016

Phase NA Unknown

250 enrolled

EndocrineNET

Neuroendocrine Tumors

NCT04194125 2020-11-04

Personalized CAPTEM Radiopeptide Therapy of Advanced, Non-resectable Neuroendocrine Cancer

Phase 2 Unknown

25 enrolled

EndocrineNET

Neuroendocrine Tumors

Clinical Trials

LEVEL

KinLET

COMPOSE

START-NET

COMPETE

LUFOR

PUTNET

177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs

FENET-2016

Personalized CAPTEM Radiopeptide Therapy of Advanced, Non-resectable Neuroendocrine Cancer